title: Subtype-selective sodium channel blockers promise a new era of pain research.
authors.affiliation: Department of Ion Channels, Merck Research Laboratories, Rahway, NJ 07065, USA. birgit_priest@merck.com
authors.forename: Birgit T
authors.initials: BT
authors.lastname: Priest
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Kaczorowski
mesh_terms: D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D006801:Humans; D007249:Inflammation; D008297:Male; D020422:Mononeuropathies / Q000628:therapy; D062559:NAV1.8 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors; D010146:Pain / Q000139:chemically induced / Q000473:pathology*; D059408:Pain Management; D051381:Rats; D026941:Sodium Channel Blockers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D015222:Sodium Channels / Q000378:metabolism
chemical_list: D000700:Analgesics; D062559:NAV1.8 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins; C568317:SCN10A protein, human; C568319:Scn10a protein, rat; D026941:Sodium Channel Blockers; D015222:Sodium Channels